

Board and Management Changes

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") advises of the following changes to its Board and management team.

The Company is pleased to announce the appointment of Mr Andrew Chapman as a Non-Executive Director.

Mr Chapman is the Founder of Merchant Funds Management and has over 25 years' experience in the financial services industry. He has spent his career in the financial markets advising many biotechnology companies on capital raisings and capital markets strategy and execution.

Mr Chapman is currently a Non-Executive Director of Argent BioPharma Ltd (ASX: RGT) and Chairman of Cycliq Group Ltd (ASX: CYQ). He holds a Bachelor of Commerce and a Post Graduate Diploma in Finance & Investment.

In addition, the Company advises that:

- Dr Anthony Filippis has resigned from his position as CEO and Managing Director.
- Subject to shareholder approval of the election of Mr Chapman as a director at the 2026 Annual General Meeting ("AGM"), Mr Robert Maxwell Johnston will retire as a director following the Company's 2026 AGM. The 2026 AGM is currently scheduled to be held on 5 November 2026.

The Company confirms that Mr Mark Davies will remain in his position as Executive Chairman, providing continuity of leadership following the Board and management changes outlined above.

The Company would like to take this opportunity to welcome Mr Chapman to the Board and looks forward to his contribution. The Company also thanks Dr Filippis and Mr Johnston for their valuable contributions to the Company during their time in office and wishes them well in their future endeavours.

Authority

This announcement was authorised for release by the Board of Neurotech International Limited.

For further information contact us via info@neurotechinternational.com

About NTI164

NTI164 is a proprietary, multi-constituent, GMP-grade standardised formulation containing CBDA-rich extracts and select minor cannabinoids. Preclinical and earlier clinical findings have demonstrated its potential to modulate neuroinflammatory signalling, immune dysregulation and upstream biological mechanisms implicated in neurodevelopmental disorders.

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, doubleblind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated

measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase III Clinical Study in ASD.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

For personal use only